A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
- Conditions
- Hormone ImbalancePolycystic Ovary Syndrome
- Interventions
- Dietary Supplement: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement
- Registration Number
- NCT06158932
- Lead Sponsor
- Optify
- Brief Summary
This is a virtual single group study that will last 12 weeks. 40 female participants will take 4 capsules of the Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement per day. Questionnaires will be completed at Baseline, Week 4, Week 8 and Week 12. Participants will also provide a waist circumference measurement at Baseline and Week 12.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 40
- Women aged between 18 - 55
- BMI less than 35
- Self-reported symptoms of PCOS like irregular periods, excessive hair growth, weight gain, oily skin, or acne
- Self-reported concerns around irregular menstrual cycles and ovulation, mood swings, stress, irritability, and low energy
- Self-reported concerns with hormonal skin issues
- Has access to a tape measure for waist measurement
- Generally healthy - don't live with any uncontrolled chronic disease
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Anyone with known severe allergic reactions
- Anyone who is pregnant or breastfeeding
- Unwilling to follow the study protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Myo Inositol and D-Chiro Inositol Supplement Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement Participants must take 4 capsules per day, with water. The product should be taken with the last meal of the day.
- Primary Outcome Measures
Name Time Method Changes in menstrual cycle regularity. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires with participants reporting menstrual cycle occurrence and regularity during the trial.
Changes in hormonal skin issues. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in excessive body hair or facial hair. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in severity of menstrual cramps. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
- Secondary Outcome Measures
Name Time Method Changes in sleep quality. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in energy. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in mood. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in stress. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Changes in food cravings. [Timeframe: Baseline to Week 12] 12 weeks Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Citruslabs
🇺🇸Santa Monica, California, United States